Traws Pharma announced plans to develop clinical candidates targeting hantavirus infections, a serious rodent-borne virus with a high fatality rate. The company leverages its antiviral drug portfolio, already active against similar RNA viruses like influenza and COVID-19, to quickly identify effective treatments. There are currently no approved therapies for hantavirus pulmonary disease, making this development critical amid recent outbreaks. Traws aims to expedite drug development and stockpile treatments for emergency use and national security.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
The producer price index (PPI) dropped by 0.3% in June following a slowdown in May, signaling easing inflation alongside a recent deflationary consumer price index (CPI) report. Real average hourly earnings rose 0.8% in June, marking the best wage ga...
President Donald Trump revealed that the US conducted another strike on Iran within 24 hours, aiming to dismantle the Iranian Revolutionary Guard Corps (IRGC), which he claims has lost about 90% of its weapons capabilities. Speaking at the Pennsylvan...
Ondo Finance announced the launch of the first tokenized equity representations using DTC tokenized entitlements, part of the DTCC Tokenization Service. This milestone pushed the ONDO token price up by about 5% and increased trading volume by 51.7% i...
